[go: up one dir, main page]

KR920002629A - B형 간염 코어 항원의 아미노산 잔기 서열 - Google Patents

B형 간염 코어 항원의 아미노산 잔기 서열 Download PDF

Info

Publication number
KR920002629A
KR920002629A KR1019910013072A KR910013072A KR920002629A KR 920002629 A KR920002629 A KR 920002629A KR 1019910013072 A KR1019910013072 A KR 1019910013072A KR 910013072 A KR910013072 A KR 910013072A KR 920002629 A KR920002629 A KR 920002629A
Authority
KR
South Korea
Prior art keywords
polypeptide
immunogen
cell stimulating
virus
complex
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
KR1019910013072A
Other languages
English (en)
Inventor
페라리 카를로
코루시 쥬세페
Original Assignee
코루시 쥬세페
클로니트 에스.피.에이
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 코루시 쥬세페, 클로니트 에스.피.에이 filed Critical 코루시 쥬세페
Publication of KR920002629A publication Critical patent/KR920002629A/ko
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • External Artificial Organs (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

내용 없음

Description

B형 간염 코어 항원의 아미노산 잔기 서열
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제1도 내지 4도는 HBV 급성 감염기간 동안 HBcAg, 서열식(Ⅰ)의 펩타이드, 및 2개의 다른 T세포 자극 펩타이드에 대한 말초혈 단핵구 증식 반응을 나타낸다.

Claims (11)

  1. 하기 서열식(Ⅰ)의 아미노산으로 필수적으로 구성된 T세포 자극 폴리펩타이드.
    PHHTALRQLCWGELMTLA (Ⅰ)
  2. 폴리펩타이드 면역원에 작동적으로 결합된 제1항에 따른 T세포 자극 폴리펩타이드를 함유하는 복합 폴리펩타이드 면역원.
  3. 제2항에 있어서, T세포 자극 폴리펩타이드가 폴리펩타이드 면역원에 아미노산 잔기 측쇄를 통해 작동적으로 결합된 면역원.
  4. 제2항에 있어서, T세포 자극 폴리펩타이드가 폴리펩타이드 면역원에 펩타이드 결합을 통해 작동적으로 결합된 면역원.
  5. 제2항에 있어서, T세포 자극 폴리펩타이드가 리포좀 또는 면역자극 컴플렉스내에 포착되어 폴리펩타이드 면역원에 작동적으로 결합된 면역원.
  6. 제2항 또는 5항중 어느 한항에 있어서, 폴리펩타이드 면역원이 바이러스, 세균, 진균 또는 원생동물의 항체-유도 에피토프를 함유하는 면역원.
  7. 제6항에 있어서, 에피토프가 B형 간염 바이러스, 인플루엔자 바이럿, 발-및-입 질환 바이러스, 폴리오바이러스, 헤르페스 심플렉스 바이러스, 광견병 바이러스, 사람 면역결핍증 바이러스 또는 플라스모듐 팔시파룸(Plasmodium falciparum)의 에피토프인 면역원.
  8. 제2항 내지 5항중 어느 한항에 있어서, 폴리펩타이드 면역원이 HSaAg 또는 HBsAg의 아미노산 서열의 폴리펩타이드 함유 부분인 면역원.
  9. 제1항에 따른 T세포 자극 폴리펩타이드를 화학적으로 합성하거나 재조합 DNA 방법으로 제조함을 특징으로하는, 제1항에 따른 T세포 자극 폴리펩타이드의 제조 방법.
  10. 제1항에 따른 T세포 자극 폴리펩타이드를 폴리펩타이드 면역원에 작동적으로 결합시킴을 특징으로 하는, 제21항에 따른 복합 폴리펩타이드 면역원의 제조 방법.
  11. 약제학적으로 허용되는 담체 또는 희석제 및 제1항에 따른 T세포 자극 폴리펩타이드 또는 제2 내지 8항중 어느 한 항에 따른 복합 폴리펩타이드 면역원을 함유하는 백신.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019910013072A 1990-07-31 1991-07-30 B형 간염 코어 항원의 아미노산 잔기 서열 Abandoned KR920002629A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9016727.1 1990-07-31
GB909016727A GB9016727D0 (en) 1990-07-31 1990-07-31 Amino acid residue sequence of hepatitis b core antigen

Publications (1)

Publication Number Publication Date
KR920002629A true KR920002629A (ko) 1992-02-28

Family

ID=10679903

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019910013072A Abandoned KR920002629A (ko) 1990-07-31 1991-07-30 B형 간염 코어 항원의 아미노산 잔기 서열

Country Status (9)

Country Link
EP (1) EP0469281B1 (ko)
JP (1) JP3000569B2 (ko)
KR (1) KR920002629A (ko)
AT (1) ATE90689T1 (ko)
CA (1) CA2048029A1 (ko)
DE (1) DE69100129T2 (ko)
DK (1) DK0469281T3 (ko)
ES (1) ES2058992T3 (ko)
GB (1) GB9016727D0 (ko)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101011358B1 (ko) * 2002-09-20 2011-01-28 세이지 까가와 폴리부틸렌 테레프탈레이트 필름의 제조 방법 및 제조장치, 및 형상 기억 폴리부틸렌 테레프탈레이트 적층 필름

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5780036A (en) * 1991-08-26 1998-07-14 The Scripps Research Institute Peptides for inducing cytotoxic T lymphocyte responses to hepattis B virus
US6607727B1 (en) 1991-08-26 2003-08-19 The Scripps Research Institute Peptides for inducing cytotoxic T lymphocyte responses to hepatitus B virus
AU679901B2 (en) * 1991-08-26 1997-07-17 Scripps Research Institute, The Peptides for inducing cytotoxic T-lymphocyte responses to hepatitis B virus
US6689363B1 (en) 1992-01-29 2004-02-10 Epimmune Inc. Inducing cellular immune responses to hepatitis B virus using peptide and nucleic acid compositions
US7611713B2 (en) 1993-03-05 2009-11-03 Pharmexa Inc. Inducing cellular immune responses to hepatitis B virus using peptide compositions
US6235288B1 (en) 1992-08-26 2001-05-22 The Scripps Research Institute Peptides for inducing cytotoxic T lymphocyte responses to hepatitis B virus
JP3649460B2 (ja) * 1993-11-05 2005-05-18 明治乳業株式会社 スギ花粉アレルゲンＣｒｙ ｊ ＩＩエピトープ
JP4176820B2 (ja) * 1993-11-05 2008-11-05 明治乳業株式会社 スギ花粉アレルゲンＣｒｙｊＩＩエピトープ
DE19901009A1 (de) * 1999-01-13 2000-07-20 Deutsches Krebsforsch Peptide zur Inhibierung von HBV-Core-Proteinen
GB0006693D0 (en) * 2000-03-20 2000-05-10 Glaxo Group Ltd Vaccine

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101011358B1 (ko) * 2002-09-20 2011-01-28 세이지 까가와 폴리부틸렌 테레프탈레이트 필름의 제조 방법 및 제조장치, 및 형상 기억 폴리부틸렌 테레프탈레이트 적층 필름

Also Published As

Publication number Publication date
JP3000569B2 (ja) 2000-01-17
CA2048029A1 (en) 1992-02-01
EP0469281A1 (en) 1992-02-05
DE69100129T2 (de) 1993-09-23
ATE90689T1 (de) 1993-07-15
DK0469281T3 (da) 1994-01-03
DE69100129D1 (de) 1993-07-22
GB9016727D0 (en) 1990-09-12
EP0469281B1 (en) 1993-06-16
ES2058992T3 (es) 1994-11-01
JPH05213995A (ja) 1993-08-24

Similar Documents

Publication Publication Date Title
GB9007024D0 (en) Novel vaccine
US5019383A (en) Fatty acid carriers for synthetic peptides
PT101052A (pt) Proteinas hibridas uteis na preparacao de vacinas
AU591054B2 (en) Pre-S gene coded peptide hepatitis B immunogens, vaccines and diagnostics
CA2329772A1 (en) Artificial t helper cell epitopes as immune stimulators for synthetic peptide immunogens
DE68928130D1 (de) Synthetische vom HIV-GP120-env-Protein abgeleitete Peptide und ihre Anwendung
RU93058563A (ru) Полипептиды, иммунореагент, способ определения антител, способ индукции иммунного ответа, композиции, способ получения полипептида
KR920002629A (ko) B형 간염 코어 항원의 아미노산 잔기 서열
EP0342860A3 (en) Novel protein, sequences containing the gene therefore, vectors, methods of preparation and use
EP0317804A3 (en) Hiv peptides and methods for detection of hiv
RU96108781A (ru) Пептиды, создающие нейтрализующие антитела к генетически дифергентным штаммам вич-1
DE69231705D1 (de) Gag-Env Fusion-Antigen aus HIV
ATE175445T1 (de) Verfahren zur gewinnung von rekombinantem hepatitis b virus (hep b) oberflächeantigen
CA1292690C (en) Vaccine comprising an immunogenic protein and, as an adjuvant, a substantially non-immunogenic sequentially homologous peptide
EP0093851A2 (en) Fatty acid carriers for synthetic vaccines
Ducos et al. Hepatitis B virus (HBV)-specific in vitro antibody production by peripheral blood mononuclear cells (PBMC) after vaccination by recombinant hepatitis B surface antigen (rHBsAg)
DE3750914T2 (de) Komplexes Immunogen, das synthetische Peptide enthält.
ATE115964T1 (de) Non-a non-b sequenzen.
BE1000167A4 (fr) Antigene du virus de l'hepatite b et procede pour sa production.
Andre Development and clinical studies with a recombinant DNA hepatitis B vaccine
Ivanoff et al. Human immunodeficiency virus antigen.
JPH05271282A (ja) 環状主要ｈｉｖ中和決定基とｔ細胞刺激エピトープとを含む合成ペプチド
KR970021095A (ko) C형 간염 바이러스에 대한 항체 검출 및 면역원으로 유용한 합성 펩타이드
IT1246322B (it) Procedimento per la preparazione di farmaci per la cura dell'epatite bcaratterizzato dal fatto di identificare il recettore della transferrina come struttura di membrana responsabile dell'infezione; e farmaci cosi' ottenuti.
TH4070A (th) ลำดับ dna ที่มีรหัสของเซอร์เฟสแอนติเจนโปรตีน p31 ที่ดัดแปลงของไวรัสเฮพพาทิทิส บี

Legal Events

Date Code Title Description
PA0109 Patent application

Patent event code: PA01091R01D

Comment text: Patent Application

Patent event date: 19910730

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 19960729

Comment text: Request for Examination of Application

Patent event code: PA02011R01I

Patent event date: 19910730

Comment text: Patent Application

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 19981102

NORF Unpaid initial registration fee
PC1904 Unpaid initial registration fee